Vinidh Paleri

Vinidh Paleri

Auto-generated profile, based on publicly available information

Vinidh Paleri

The Royal Marsden NHS Foundation Trust, London, United Kingdom

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Oral Oncology
Verified
Journal Article
Closed access
VPVinidh Paleri
Vinidh Paleri
RWRichard G. Wight
Richard G. Wight
CSCarl E. Silver
Carl E. Silver
MHMissak Haigentz
Missak Haigentz
RTRobert P. Takes
Robert P. Takes
AFAlfio Ferlito
Alfio Ferlito

11 March 2014 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
VPVinidh Paleri
Vinidh Paleri
MDMike Drinnan
Mike Drinnan
MBMichiel W. M. van Den Brekel
Michiel W. M. van Den Brekel
MHMichael L. Hinni
Michael L. Hinni
PBPatrick J. Bradley
Patrick J. Bradley
AFAlfio Ferlito
Alfio Ferlito

1 February 2001 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
VPVinidh Paleri
Vinidh Paleri
SGS. Gopalakrishnan
S. Gopalakrishnan

4 July 2013 in Head & Neck
Verified
Journal Article
Closed access
PDF file
VPVinidh Paleri
Vinidh Paleri
JRJustin W. G. Roe
Justin W. G. Roe
PSPrimož Strojan
Primož Strojan
JCJune Corry
June Corry
VGVincent Grégoire
Vincent Grégoire
AFAlfio Ferlito
Alfio Ferlito

12 May 2016 in The Journal of Laryngology & Otology
Verified
Journal Article
Open access
PDF file
VPV Paleri
V Paleri
TUT G Urbano
T G Urbano
HMHisham Mehanna
Hisham Mehanna
CRC Repanos
C Repanos
JLJ Lancaster
J Lancaster
MSM Sen
M Sen
This is the official guideline endorsed by the specialty associations involved in the care of head and neck cancer patients in the UK. A rational plan to manage the neck is necessary for all head and neck primaries. With the emergence of new level 1 evidence across several domains of neck metastases, this guideline will identify the evidence-based recommendations for management.Recommendations: • Computed tomographic or magnetic resonance imaging is mandatory for staging neck disease, with choice of modality dependant on imaging modality used for the primary site, local availability and expertise. (R)• Patients with a clinically N0 neck, with more than 15–20 per cent risk of occult nodal metastases, should be offered prophylactic treatment of the neck. (R)• The treatment choice of for the N0 and N+ neck should be guided by the treatment to the primary site. (G)• If observation is planned for the N0 neck, this should be supplemented by regular ultrasonograms to ensure early detection. (R)• All patients with T1 and T2 oral cavity cancer and N0 neck should receive prophylactic neck treatment. (R)• Selective neck dissection (SND) is as effective as modified radical neck dissection for controlling regional disease in N0 necks for all primary sites. (R)• SND alone is adequate treatment for pN1 neck disease without adverse histological features. (R)• Post-operative radiation for adverse histologic features following SND confers control rates comparable with more extensive procedures. (R)• Adjuvant radiation following surgery for patients with adverse histological features improves regional control rates. (R)• Post-operative chemoradiation improves regional control in patients with extracapsular spread and/or microscopically involved surgical margins. (R)• Following chemoradiation therapy, complete responders who do not show evidence of active disease on co-registered positron emission tomography–computed tomography (PET–CT) scans performed at 10–12 weeks, do not need salvage neck dissection. (R)• Salvage surgery should be considered for those with incomplete or equivocal response of nodal disease on PET–CT. (R)

8 March 2002 in The Journal of Laryngology & Otology
Verified
Journal Article
Closed access
PDF file
VPV. Paleri
V. Paleri
RWR. G. Wight
R. G. Wight
The term comorbidity stands for disease processes that co-exist and are not related to the index disease being studied. Comorbidity in cancer has been shown to be a major determinant in treatment selection and survival. Patients with head and neck cancer can have significant comorbidity owing to the high incidence of tobacco and alcohol abuse. No studies to date have addressed this problem in head and neck cancer patients in the United Kingdom. The applicability of the adult comorbidity evaluation – 27 index (ACE-27) and the Charlson index (CI) to assess the comorbidity burden by retrospective notes review is studied here. Retrospective data collection and completion of a comorbidity index in a United Kingdom setting is feasible. We conclude that the pre-assessment visit is a useful time to record comorbidity and as a significant amount of information required for grading relates to historical items, this is best done using a self-administered patient questionnaire.